Dio Tree develops a novel, first in class, small molecule for the treatment of ovarian cancer. The new technology is based on inhibition of the enzyme DIO3, which is a major driver in many types of cancer, and specifically, in ovarian cancer.


The enzyme DIO3 is responsible for breaking down thyroid hormones, including the biological hormone T3. Because T3 has anti-cancer functions, many tumors express this enzyme, thereby facilitating the division of cancer cells. DIO3 is highly expressed in high grade serous ovarian cancer (HGSOC), an aggressive disease with disproportional mortality rates. The technology involves a series of small molecules, the first of their kind for specific targeting of DIO3.


HGSOC is a therapeutic challenge. Despite existing treatments (chemotherapy, PARP inhibitors and VEGF inhibitors), most patients develop resistance resulting in extremely low survival rates. The global ovarian cancer patient market represents about 300,000 patients per year. This market is expected to grow by nearly 40% by 2040. Ovarian cancer is considered by the FDA as an orphan disease and therefore the regulatory pathway is fast and with leniencies in development. Hence DIO3 inhibition is a new targeted therapy in a novel pathway, which could give new hope for patients that become resistant to existing therapies that act by other mechanisms of action. Finally, the DIO3 enzyme is expressed in additional aggressive tumors, including breast and lung cancer, which represents an even greater market potential for this technology.


Dr. Sarit Batsir CEO. Sarit has a Ph.D. in life science from the Weizmann Institute of science. She gained more than 8 years of experience span across the healthcare industry including clinical trials, medical regulations, commercial strategics, business development, licensing, initiating and managing legal aspects and patents.

Prof. Osnat Ashur-Fabian Founder & CSO. Osnat received her Ph.D from the Sackler Faculty of Medicine at the Tel-Aviv University, where she is currently an Associate Professor. Osnat is the director of the Translational Oncology Research at Meir Medical Center with more than 20 years of experience in cancer research. Osnat is the inventor of several patents and has prior vast experience in commercializing new cancer treatments

Dotan Moskovich, M.Sc, R&D. Dotan is currently finishing her Ph.D at the Translational Oncology Research Laboratory at Meir Medical Center, affiliated to the Sackler Faculty of Medicine, Tel-Aviv University. Under the supervision of Prof. Ashur-Fabian, Dotan accumulated vast expertise both in basic and translational oncological research, focusing on ovarian cancer.


Dr. Sarit Batsir (PhD), CEO

972(052)-6283780 | Sarit@Dio-Tree.com

POB 1252, Nazareth, 1711102, Israel